ZA202000882B - Method - Google Patents

Method

Info

Publication number
ZA202000882B
ZA202000882B ZA2020/00882A ZA202000882A ZA202000882B ZA 202000882 B ZA202000882 B ZA 202000882B ZA 2020/00882 A ZA2020/00882 A ZA 2020/00882A ZA 202000882 A ZA202000882 A ZA 202000882A ZA 202000882 B ZA202000882 B ZA 202000882B
Authority
ZA
South Africa
Prior art keywords
subjects
myelin
subject
dementia
demyelination
Prior art date
Application number
ZA2020/00882A
Other languages
English (en)
Inventor
Martin Keith
Jansson Liselotta
Original Assignee
Apitope Tech Bristol Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713036.0A external-priority patent/GB201713036D0/en
Priority claimed from GBGB1713037.8A external-priority patent/GB201713037D0/en
Priority claimed from GBGB1713035.2A external-priority patent/GB201713035D0/en
Application filed by Apitope Tech Bristol Limited filed Critical Apitope Tech Bristol Limited
Publication of ZA202000882B publication Critical patent/ZA202000882B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2020/00882A 2017-08-14 2020-02-11 Method ZA202000882B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1713036.0A GB201713036D0 (en) 2017-08-14 2017-08-14 Method
GBGB1713037.8A GB201713037D0 (en) 2017-08-14 2017-08-14 Method
GBGB1713035.2A GB201713035D0 (en) 2017-08-14 2017-08-14 Method
PCT/GB2018/052304 WO2019034862A1 (en) 2017-08-14 2018-08-14 Method

Publications (1)

Publication Number Publication Date
ZA202000882B true ZA202000882B (en) 2023-08-30

Family

ID=63294371

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/00882A ZA202000882B (en) 2017-08-14 2020-02-11 Method

Country Status (8)

Country Link
US (1) US20210093695A1 (enExample)
EP (1) EP3668535A1 (enExample)
JP (1) JP7419229B2 (enExample)
CN (1) CN111225681A (enExample)
AU (2) AU2018316662A1 (enExample)
CA (1) CA3072867A1 (enExample)
WO (1) WO2019034862A1 (enExample)
ZA (1) ZA202000882B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
WO2023100758A1 (ja) * 2021-11-30 2023-06-08 国立大学法人京都大学 ペプチド含有組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO2009056833A2 (en) * 2007-10-31 2009-05-07 Apitope Technology (Bristol) Limited Composition
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201300683D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10759838B2 (en) * 2015-03-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Also Published As

Publication number Publication date
WO2019034862A1 (en) 2019-02-21
CA3072867A1 (en) 2019-02-21
JP2020530846A (ja) 2020-10-29
JP7419229B2 (ja) 2024-01-22
AU2018316662A1 (en) 2020-02-20
US20210093695A1 (en) 2021-04-01
AU2025201115A1 (en) 2025-03-06
EP3668535A1 (en) 2020-06-24
CN111225681A (zh) 2020-06-02

Similar Documents

Publication Publication Date Title
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2024005935A (es) Metodos para aumentar la exposicion al plasma de sepiapterina.
MY198587A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2018004553A (es) Combinación farmacéutica de un antipsicótico atípico y un modulador de nmda para el tratamiento de esquizofrenia, trastorno bipolar, deterioro cognitivo y trastorno depresivo mayor.
ZA202000882B (en) Method
EP4054620C0 (en) SEMAGLUTIDE FOR THE TREATMENT OF ALZHEIMER’S DEMENTIA
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
MY207073A (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2016134257A8 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
MX2018013507A (es) Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.
MX2021001877A (es) Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2018013468A (es) Metodos y formulaciones para el tratamiento y/o prevencion de trastornos relacionados con la sangre.
MX2023008840A (es) Formulaciones de oxitocina que contienen magnesio y metodos de uso.
WO2019245347A3 (ko) 신경퇴행성 질환 예방 또는 치료용 조성물
GB2567398A (en) Method and composition for treating dysbiosis and related disease states
MX2021002653A (es) Uso de moduladores de cftr para el tratamiento de condiciones cerebrovasculares.
ZA202004559B (en) Phytoconstituent for treating diabetes
PH12020500645A1 (en) Treatment of disorders with tasimelteon